Tribute Pharma (TBUFF-OTC)

TBUFF: Strong Q2 results, Revenues up by 21.4% QoQ. Expect revenue to improve in 2014

OUTLOOK
Currently trading at $0.56 a share with a market cap of $29M, we feel Tribute’s shares are undervalued. TBUFF’s strategy of in-licensing late-stage pharmaceutical products and marketing to under-served markets has substantially increased their revenue. The higher margin primary care products (CAMBIA, Bezalip SR and Soriatane) have shown double digit growth since their launch and are just starting to pick up speed. We are positive on Tribute’s ability to add new licensed products to their portfolio. Based on Tribute’s streamlined operations and efficiency, along with a strong portfolio of products, we expect Tribute to build significant value in the near term. We initiate coverage on TBUFF with an Outperform rating and $1.00/share.

SUMMARY DATA

| 52-Week High | $1.10 |
| 52-Week Low | $0.32 |
| One-Year Return (%) | N/A |
| Beta | N/A |
| Average Daily Volume (sh) | 70,713 |
| Shares Outstanding (mil) | 94 |
| Market Capitalization ($mil) | $29 |
| Short Interest Ratio (days) | N/A |
| Institutional Ownership (%) | 0 |
| Insider Ownership (%) | N/A |
| Annual Cash Dividend | $0.00 |
| Dividend Yield (%) | 0.00 |

5-Yr. Historical Growth Rates

| Sales (%) | N/A |
| Earnings Per Share (%) | N/A |
| Dividend (%) | N/A |

P/E using TTM EPS | N/A |
P/E using 2014 Estimate | -15.0 |
P/E using 2015 Estimate | 10.0 |
Zacks Rank | N/A |

ZACKS ESTIMATES

Revenue (in millions of $)

<table>
<thead>
<tr>
<th>Q1 (Mar)</th>
<th>Q2 (Jun)</th>
<th>Q3 (Sep)</th>
<th>Q4 (Dec)</th>
<th>Year (Dec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>3.4 A</td>
<td>3.3 A</td>
<td>3.5 A</td>
<td>3.2 A</td>
</tr>
<tr>
<td>2014</td>
<td>3.5 A</td>
<td>4.0 A</td>
<td>4.0 E</td>
<td>4.4 E</td>
</tr>
<tr>
<td>2015</td>
<td>21.0 E</td>
<td>27.0 E</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Earnings per Share

(EPs is operating earnings before non recurring items)

<table>
<thead>
<tr>
<th>Q1 (Mar)</th>
<th>Q2 (Jun)</th>
<th>Q3 (Sep)</th>
<th>Q4 (Dec)</th>
<th>Year (Dec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>-0.04 A</td>
<td>-0.03 A</td>
<td>-0.02 A</td>
<td>-0.03 A</td>
</tr>
<tr>
<td>2014</td>
<td>-0.07 A</td>
<td>-0.09 A</td>
<td>-0.02 E</td>
<td>-0.01 E</td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Zacks Projected EPS Growth Rate - Next 5 Years % | N/A
WHATS NEW

- From May 3, 2014 Tribute began trading on the TSX-V: TRX and as of August 5, 2014 Tribute began trading on the OTCQX: TBUFF. This offers a better access to Canadian capital markets and investors.

- On May 13, 2014, Tribute entered into an exclusive license agreement with Faes Farma, S.A. (“Faes”), a Spanish pharmaceutical company, for the exclusive rights to sell Bilastine (inclusive of prescription and non-prescription for adults and pediatric patients), a product for the treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria (hives) in Canada. Tribute intends to get this long term growth product to market in 2016.

Allergic rhinitis and urticaria are both allergic conditions that impair productivity of any individual. The typical symptoms of allergic rhinitis are nasal itching, congestion, rhinorrhea and sneezing. For urticaria, the characteristic symptoms include itchy skin lesions with a central swelling and painful areas of deeper swelling involving the skin and mucous membranes. Both types of allergies are highly prevalent. According to the Canadian Allergy, Asthma and Immunology foundation, Allergic Rhinitis affects 20% to 25% of Canadians. As per IMS Health reports the Canadian oral antihistamines market had sales of approximately $120 million in 2013.

Bilastine is a non-sedating H1 antihistamine for symptomatic treatment of allergic rhinitis and urticaria in adults and children older than 12 years of age. It is an innovative and patent protected new molecule developed by Faes in Spain. Bilastine has been studied in over 30 clinical trials including 5 pivotal Phase III trials in allergic rhinitis or urticaria. Upon approval by Health Canada, Bilastine will be granted a minimum of 8 years of market exclusivity.

- Tribute completed a public equity offering of 42,895,000 common shares of stock on July 15, 2014 issued at a price of $0.70 per unit resulting in gross proceeds of just over $30 million. This is expected to aid Tribute develop its strategic initiatives related to business development and acquisition of complementing products.

- One of Tribute’s key product, CAMBIA, that was introduced for the treatment of migraine headaches, which addresses a $150 million market in Canada, has been the primary revenue driver for this quarter.

Q2 2014 Results

Financial Condition:
Revenue: Our estimates for revenue and gross margin for Q2 2014 were largely in-line with the actuals. A 21.4% increase in revenues in Q2 2014 as compared to Q2 2013 was primarily attributed to a 67% increase in domestic product sales of CAMBIA. Introduced in 2013 as part of Tribute's licensed domestic product portfolio CAMBIA almost immediately exhibited rapid sales growth. We expect this product to be a key source of revenue for Tribute in the coming years. By the end of 2013, CAMBIA had gained more than 1% market share in Canada. CAMBIA is patent protected through 2026, providing Tribute with market exclusivity for another twelve years. As per IMS health, the total prescriptions written for CAMBIA during Q2 2014 increased by 27% from the prior quarter. We continue to see strong growth in CAMBIA sales and believe it is still on target to reach a market penetration of 5% by 2016.

The investment in sales and marketing initiatives to promote CAMBIA had a spill-over effect on the remainder of Tribute's domestic products indirectly benefiting the sale of Soriatane and Bezalip SR, which had a combined increase in sales of 9.8% from Q1 to Q2 2014. Uracyst and Neovisc are Tribute's proprietary products. They have contributed modestly to the revenue growth and we expect this trend to continue through 2014.
Selling, general and administrative (SG&A) expenses decreased by 33% in Q2 2014 as compared to Q1 2014. Expense of $41,400 is related to Bezalip SR® filing in the U.S. An expense of $42,400 is related to the acquisition of Bilastine. $15,600 related to non-cash expenses for stock options issued to directors, officers and employees of the company are included in SG&A costs.

**Cash:** Cash flow used in operating activities was much lower for the 6 month period ended June 30, 2014 as compared to the same period in 2013. Cash used was $4.2M and $2.3M in the first 6 months of 2013 and 2014 respectively. This may be indicative of improving financial conditions for the company as it continues to grow its top line and expand its gross margin while optimizing expenses. The company had cash and cash equivalents of $2.3M as of June 30, 2014. With the recent share issuance resulting in an additional $30M, the company is well placed in its cash position although it may be dilutive for its shareholders.

**KEY POINTS**

- Tribute Pharmaceuticals Inc. is a specialty pharmaceutical company headquartered in Canada with annual revenues of over $13M.

- Tribute has aggressively grown its pharmaceutical business in recent years with the addition of a number of lucrative pharmaceutical products such as Bezalip SR, Soriatane and CAMBIA through strategic partnerships with global companies. These partnerships allow Tribute to acquire exclusive licenses for the sales and marketing of their products that also comes with the benefit of low R&D costs.

- The company offers a complementing portfolio of targeted therapeutic products that address a diverse set of ailments. These include a number of patented drugs which have their exclusivity locked up during which Tribute can ramp up sales of the same.

- Entering lucrative U.S. market at a time when Affordable Care Act is just commencing implementation could help Tribute's sales efforts in the U.S.

- The launch of CAMBIA in October 2012 put Tribute in direct competition with triptans in the migraine market – a full twelve years before CAMBIA's patent is due to expire. Management believes that the momentum in sales from the end of 2013 may carry forward to the next couple of years, providing significant revenue growth to the company in the short-term. The company hopes to increase the proportion of private insurers providing reimbursement for CAMBIA in an effort to speed adoption of the drug by physicians and patients.
Bezalip SR has a strong position in the Canadian dyslipidemia market and Tribute has obtained IND approval in the U.S. Bezalip SR targets aging populations and with longer life expectancies, we expect the market size for this class of drugs to grow in the coming years.

BACKGROUND

Tribute Pharmaceuticals Canada Inc. (TBUFF) is a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and management of pharmaceutical and healthcare products with a primary focus on the Canadian market. The company’s primary business is the commercialization of drugs in various therapeutic areas, such as migraine, cardiology, dermatology, pain and urology. Tribute also engages in marketing medical devices for the prevention and treatment of surgical site infections. Tribute is headquartered in Milton, Ontario, Canada and was founded in 1996. Stellar Pharmaceuticals was founded in London, Ontario in 1997 and the two companies merged in December 2011 and officially changed its name to Tribute Pharmaceuticals Canada Inc. in January 2013.

Tribute operates in the global pharmaceutical industry, which is highly competitive and tightly regulated. Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making Canada the 8th largest pharmaceutical market in the world. The national healthcare plan in Canada covers 100% of its population. For prescription drugs that are sold in Canada, approximately 10% are paid for by the patient (non-reimbursed medical expense), 45% by private insurance and 45% by government reimbursement plans. The pharmaceutical industry in Canada is comprised of brand-name products that account for 76% of Canadian sales and 37% of prescriptions. Generics account for the remainder.

<table>
<thead>
<tr>
<th>Galen</th>
<th>UK &amp; Ireland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medac</td>
<td>Germany &amp; Austria</td>
</tr>
<tr>
<td>EuroCept Pharma</td>
<td>Netherlands &amp; Belgium</td>
</tr>
<tr>
<td>CPH Companhia</td>
<td>Portugal</td>
</tr>
<tr>
<td>Laboratories Inibsa</td>
<td>Spain</td>
</tr>
<tr>
<td>Jellmedix</td>
<td>Korea</td>
</tr>
<tr>
<td>Navamedic</td>
<td>Scandinavia &amp; Iceland</td>
</tr>
<tr>
<td>Ecupharma Italia</td>
<td>Italy</td>
</tr>
</tbody>
</table>

Some of Tribute’s Global Partners (Source: tributepharma.com)

Tribute is actively partnering with Actavis (ACT: NASDAQ), Depomed Inc. (DEPO: NASDAQ) formerly Nautilus Neurosciences until Depomed acquired Nautilus in December 2013 and EUSA Pharma (JAZZ: NASDAQ) in Canada as well as with other well-known companies internationally.

Tribute sells products in both the primary care and specialty care markets. Tribute’s current portfolio includes 6 products, all 6 of which have received regulatory approval in Canada. Tribute sells CAMBIA® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution), Uracyst® (sodium chondroitin sulfate solution 2%) and Collatamp® G (gentamicin-impregnated collagen).

Additionally, the company holds an exclusive license for Bezalip SR in the U.S. Tribute is hoping to expand their operations into the US through a licensing arrangement and partnership with a US healthcare company to develop, sell and market Bezalip SR, contingent upon the approval of an NDA in the U.S. Tribute is expecting an additional
Zacks Investment Research

patent to be granted in Europe for Uracyst this year which will present new opportunities for the product and for the company, and its international partners in this market. Tribute intends to expand their visibility by selling their proprietary and licensed products in other global markets that are currently untapped.

Tribute focuses on targeting the acquisition of mature products that have undergone significant R&D and have regulatory approvals in Canada or require approvals for commercialization in global markets. In the past, Tribute has focused on research and development, manufacturing, sales and out-licensing of their proprietary products, Uracyst and NeoVisc globally. Such products address a niche market and have limited market size. The development of lucrative drugs that caters to large populations is risky due to competition from large drug companies and further, requires significant investment in research and development. It is more cost effective for a company like Tribute to in-license products like Bezalip SR that can be marketed to a larger audience. Tribute’s core business model has evolved into marketing, sales and life-cycle management of licensed products that are in the final stages of qualifying for a regulatory approval. For example, Tribute negotiates for the exclusive license to sell products developed by companies like Pfizer in the Canadian market. The expanded business model has necessitated the addition of sales and distribution infrastructure to help distribute and sell their products to doctors, hospitals and clinics throughout Canada.

Tribute acquires the licenses to market these products mainly for the Canadian market with appropriate regulatory and pre-marketing approvals containing all manufacturing, pre-clinical, and clinical trial results that for the most part lower the risks with their model. Tribute has shown strong revenue growth due to the addition of in-licensed products, however, this has added layers of selling expenses and squeezed margins due to up-front licensing fees. We expect that with the added sales force, larger customer base and a portfolio of diverse products, Tribute will be able to significantly increase their revenue and achieve positive cash flow in the near term.

PRODUCTS

Primary Care Products

CAMBIA
CAMBIA® (diclofenac potassium for oral solution) is the only available, approved, fast-acting, prescription non-steroidal anti-inflammatory drug (NSAID) in Canada for the treatment of acute migraine attacks with or without aura (feelings and symptoms a person notices shortly before the headache begins) in adults (18 years or older). CAMBIA, owned by Nautilus Neurosciences Inc., was pre-launched in Canada to neurologists and headache specialists in October 2012 and more broadly launched to Primary Care Physicians (PCPs) in February 2013. The United States and Canadian rights to CAMBIA were recently acquired by Depomed, Inc. (NASDAQ: DEPO) through the acquisition of Nautilus Neurosciences, Inc. Tribute is currently in an exclusive Canadian sub-licensing agreement with Depomed Inc. to develop, register, promote, manufacture, use, market, distribute and sell CAMBIA in Canada. CAMBIA received approval from Health Canada in March 2012.

(Source: http://www.tributepharma.com/Products/Cambia)
**Background on Migraine:** A migraine headache is a neurovascular disorder characterized by an intense throbbing or a pulsing sensation in one area of the head. It is usually accompanied by nausea, vomiting, and extreme sensitivity to light and sound. For a few people, the migraine headache is preceded or accompanied by sensory warning symptoms (aura), such as flashes of light, blind spots, or tingling sensation in the arm or leg. The initial as well as recurring attacks, which may be moderate to severe in intensity, may be triggered either by psychological, biological or environmental factors or a combination of these. Medications, if used at the time of onset of the headache, can help reduce the frequency and severity of migraines.

**Pharmacology:** Acute migraine treatment options can be broken down into three main categories: (i) triptans or 5-HT1 receptor agonists (e.g. sumatriptan, rizatriptan); (ii) ergot alkaloids (e.g. ergotamine, dihydroergotamine); and (iii) NSAIDs (e.g. CAMBIA). Additionally, β-blockers, calcium-channel blockers, serotonin-receptor agonists, tricyclic analgesics, and NSAIDS (naproxen sodium) have also been shown to be effective in prophylactic (preventive) treatment of migraine. NSAIDs and triptans (Sumatriptan) are used in moderate intensity migraine attacks. Although Sumatriptan is fast acting, it is recommended not be taken in the aura phase, and has a higher rate of headache recurrence after 24 hours. Dihydroergotamine (DHE) is a 5-HT1 receptor agonist and hence works similar to but has a longer duration of action than sumatriptan (lower recurrence rate). Generally, triptans are considered superior to ergot alkaloids from both an efficacy and side-effect perspective. However, intolerance of side effects (blood vessel constriction, chest pain/pressure/tightness, esophageal spasm, dizziness, fatigue, nausea, light headedness, etc.), is a major cause of dissatisfaction with triptan users directing the need for a viable alternative, such as CAMBIA (NSAID).

NSAIDs possess anti-inflammatory, analgesic and anti-pyretic proprieties. NSAIDs primarily act by inhibiting the enzyme cyclooxygenase with subsequent decrease in prostaglandin biosynthesis, which are involved in the pathophysiology of migraine headaches. Prostaglandins are known to be involved in excitation and sensitization of peripheral pain receptors associated with tissue damage or inflammation. Since NSAIDs inhibit the production of prostaglandins, they can be regarded as mild peripheral analgesics. NSAIDs are most effective at locations where inflammation causes the impulse discharge of polymodal thin fiber nociceptors. Among NSAIDs, the principal differences lie in the time to onset and duration of action.

Acetylsalicylic acid (ASA), ibuprofen, naproxen, and acetaminophen are known to have anti-inflammatory or sub analgesic effects and are most commonly used for mild attacks of migraine. Acetaminophen, although effective in reducing fever and offering headache pain relief, is not known to be as effective against pain associated with inflammation. NSAIDs have been a suggested replacement or a supplement to triptans for treatment of acute migraine attacks. Although NSAIDs have been a standard option for headache treatment, the speed of onset of NSAIDs as compared with triptans has been a limiting factor in their use.

Prostaglandins play a major role in causing inflammation, pain, and fever. Inhibition of prostaglandin biosynthesis has found to be the mechanism of action in clinical studies using the potassium salt of diclofenac (the active ingredient in Cambia). CAMBIA was specifically developed to address a widespread underserved need among migraine sufferers for quick relief of headache and associated symptoms such as nausea, sensitivity to light and sensitivity to sound. CAMBIA is not indicated for prophylactic therapy of migraines attacks nor is it indicated for other types of headaches.

In a clinical trial involving diclofenac in powder form, tablet and a placebo, CAMBIA demonstrated that its composition significantly offers pain-free symptoms in moderate to severe headache with sustained relief for 24 hours post treatment and reduction of the associated symptoms of migraine compared with diclofenac in tablet form and placebo. CAMBIA offers a first-line treatment for migraine, in treatment for patients who cannot tolerate or do not respond to other medications, and/or as an adjunctive treatment to existing pain-relief options. It can additionally be helpful to patients who are unable to swallow tablets, as CAMBIA is in powder form and can be

---

1 William E.M. Pryse-Phillips, MD; David W. Dodick, MD; John G. Edmeads, MD; Marek J. Gawel, MD; Robert F. Nelson, MD; R. Allan Purdy, MD; Gordon Robinson, MD; Denise Stirling, MD; Irene Worthington (1997), BScPhm, Guidelines for the diagnosis and management of migraine in clinical practice, Journal of Canadian Medical Association ;156:1273-87


dissolved to form an oral solution. Once dissolved in liquid, CAMBIA has a rapid onset of pain-relief (15 minutes)\(^4\) while the pharmacokinetic data showed other oral tablets such as ibuprofen, and naproxen sodium took effect up to two hours after consumption.

![Graph showing plasma concentration over time for diclofenac potassium, ibuprofen, and naproxen sodium.](Image)

**Achievement of Peak Absorption for Tablets can take up to Two Hours vs. 15 Minutes for CAMBIA**

(Source: www.tributepharma.com)

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Type</th>
<th>Salt Form</th>
<th>Form</th>
<th>Tmax(^1)</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambia®</td>
<td>NSAID</td>
<td>potassium</td>
<td>Power for oral solution</td>
<td>15 minutes</td>
<td>Acute migraine</td>
</tr>
<tr>
<td>Catafam®</td>
<td>NSAID</td>
<td>potassium</td>
<td>Immediate release tablets</td>
<td>1 hour</td>
<td>Acute pain/osteoarthritis</td>
</tr>
<tr>
<td>Voltaren®</td>
<td>NSAID</td>
<td>sodium</td>
<td>Immediate release tablets</td>
<td>2.5 hours</td>
<td>Rheumatoid &amp; osteoarthritis</td>
</tr>
<tr>
<td>Voltaren®-XR</td>
<td>NSAID</td>
<td>sodium</td>
<td>Slow release tablets</td>
<td>3.3 hours</td>
<td>Rheumatoid &amp; osteoarthritis</td>
</tr>
<tr>
<td>Zipsor®</td>
<td>NSAID</td>
<td>potassium</td>
<td>Oral liquid filled capsules</td>
<td>47 minutes</td>
<td>Mild to moderate acute pain</td>
</tr>
<tr>
<td>Zorvolex®</td>
<td>NSAID</td>
<td>potassium</td>
<td>Immediate release capsules</td>
<td>3.32 hours</td>
<td>Mild to moderate acute pain</td>
</tr>
</tbody>
</table>

\(^1\) Tmax = maximum threshold; time to maximum [concentration] of the drug

The triptan class of drugs (also known as the 5-hydroxytryptamine agonists) remains the most commonly prescribed medications for migraine in Canada. There are seven approved triptans in Canada including, Relpax® (eletriptan) Pfizer, Imitrex® (sumatriptan) GSK, Axert® (almotriptan) Johnson & Johnson, Zomig® (zolmitriptan) Astra Zeneca, Amerge® (naratriptan) GSK, Frova® (frovatriptan) Teva Neuroscience and Maxalt® (rizatriptan) Merck. These products are popular drug choices for migraine in Canada and are only available by prescription. All seven of these products have lost their market exclusivity in Canada except for Frova. The patents have expired on Frova but as of the writing of this report, no generics have yet been introduced in Canada. Sumatriptan, a generic equivalent, holds about 24% market share of the migraine market in Canada. Branded products range in retail price from $5 to $25 per tablet compared to generic diclofenac potassium 50 mg tablets that sells for around $0.07 to $0.20 per tablet. Cambia is the only medication for acute migraine that is actively promoted to physicians in Canada.

**Migraine Market (Canada)**

Management estimates the prescription migraine market in Canada is valued at about $140 million. An estimated 4 million people suffer from migraine headaches, with approximately 60% of sufferers experiencing two or more attacks per month and 25% having at least one attack per month. Migraines disproportionately affect women at a rate of 3 to 1 and are the most common among people between the ages of 25 and 55. Migraine is inadequately treated. We estimate that most of this age group is backed by private insurance and will additionally benefit from the co-pay assistance cards (rebate to cover all or part of the copay cost of the medication) issued by the manufacturer.

Despite the available third-party reimbursement, we think that most patients initially seek self-treatment with over-the-counter (OTC) medications. OTC medications such as Advil (ibuprofen), Aleve (naproxen), and Excedrin (acetaminophen / aspirin combination), help relieve the symptoms of an acute attack, are affordable and readily available. Of those patients who seek medical help, a majority go to PCPs, rather than specialists as a first step. As a result, most prescriptions come from PCPs. The PCP, as compared to a neurologist has very little specialized training related to migraine diagnosis and treatments. By contrast, a neurologist is well-informed on the research regarding migraine, typically will spend time with the patient to diagnose and assess the impact of pain on the patient, has a clear understanding of the appropriate treatments available, has more knowledge in communicating these benefits to the patients and can offer practical strategies to reduce the occurrence of the migraine attack. Therefore, the adoption of new drugs in the migraine market is readily welcomed by specialists, especially neurologists. However, since most prescriptions come from PCPs rather than neurologists, we believe that Tribute is making a good move by marketing CAMBIA to PCPs. This will help boost CAMBIA sales in the Canadian market.

**Bezali SR**
Tribute also offers Bezali SR (bezafibrate) to the Canadian market. Bezali SR is a pan-peroxisome proliferator-activated receptor (pan-PPAR) activator to treat hyperlipidemia. Bezali SR is approved in over 40 countries across the globe.

**Background on Hyperlipidemia:** Lipids are composed mainly of cholesterol, triglycerides (fatty acid molecules), lipoproteins, and phospholipids. Hyperlipidemia is a very common chronic condition and is characterized by abnormal elevation in levels of plasma cholesterol, and/or triglycerides (TGs), and/or lipoproteins. Hyperlipidemia, in general, can be divided into two subcategories: Hypercholesterolemia, in which there is a high level of cholesterol; and Hypertriglyceridemia (HTG), in which there is a high level of triglycerides, the most common form of fat.

**Pharmacology:** Severe hypertriglyceridemia (SHTG) is a condition in which triglyceride levels are elevated, often caused or exacerbated by uncontrolled diabetes mellitus, obesity, and sedentary habits. High levels of cholesterol and triglycerides have been shown to increase the risk of atherosclerosis, angina and heart attacks (coronary artery disease). Bezali SR belongs to a family of fibrates used for treating patients with SHTG.

In clinical trials, Bezali SR has been shown to significantly reduce triglyceride levels, increase high-density lipoproteins (HDL) levels while providing small decreases in low-density lipoproteins (LDL) thereby improving the lipid profile. Bezali SR'S unique mechanism of action may provide certain advantages compared to other currently marketed products, including an increase in insulin sensitivity, especially in patients with type 2 diabetes.

Bezali SR, 400mg tablet, is designed for sustained release of the bezafibrate continuously over the day so that only one dose is required to be taken each day. The tablets must be swallowed whole to avoid damaging the sustained-release action.

Cholesterol-lowering drugs currently offered in the market include statins, niacin, bile-acid resins, fibric acid derivatives (fibrates), and cholesterol absorption inhibitors. All classes of cholesterol-lowering medicines are most effective when combined with therapeutic lifestyle changes such as increased exercise and a low-fat, high-fiber diet. Statins are most commonly used for people who require LDL-lowering therapy. The statin class includes some of the largest-selling prescription products in the world (Lipitor®, Zocor®, Crestor®, etc.). Statins dominate single-agent

---

prescriptions for the treatment of lipid disorders. Fibrates or niacin is beneficial for people who need to lower triglycerides and increase high-density lipoprotein. The niacin (nicotinic acid – vitamin B3) class includes brands such as Niaspan®, which work primarily on increasing HDL cholesterol. The fibrates class of cholesterol lowering treatments is composed of three competing molecules: gemfibrozil (Lopid®), bezafibrate (Bezalip SR), and fenofibrate (Lipidil® in Canada or Tricor® in the U.S.). Omega 3 fatty acids (Lovaza®, Vascepa®) may reduce the synthesis of triglycerides in the liver because eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are poor substrates for the enzymes responsible for triglyceride synthesis, and EPA and DHA inhibit esterification of other fatty acids.

All fibrates are PPARs-alpha agonists that have the ability to decrease triglyceride and increase HDL. However, bezafibrate has a unique characteristic profile of action since it activates all three PPAR subtypes (alpha, gamma and delta) at comparable doses. Unlike other fibrates, bezafibrate decreases blood glucose level, HbA1C, insulin resistance, and reduces the incidence of type 2 diabetes. Bezafibrate significantly decreased LDL levels, induced atherosclerotic plaque regression in thoracic and abdominal aorta and improved endothelial function. In clinical trials bezafibrate was highly effective for cardiovascular risk reduction in patients with metabolic syndrome and atherogenic dyslipidemia. Although evidence supports statin’s role in treating dyslipidemia (LDL was reduced) as well as preventing cardiovascular events (atherosclerosis), fibrates, including bezafibrate, have shown a stronger effect on triglycerides and HDL than statins. Bezafibrate has consistently shown a significant beneficial effect on patients with type 2 diabetes and high lipid levels. Further, recent reports have indicated that there is potential for statins to slightly increase diabetes risk. Studies done on bezafibrate monotherapy showed that it may be appropriate for treating early-onset type 2 diabetes coexisting with hypertriglyceridemia. On the other hand, studies suggest that hyperglycemic patients with poor blood glucose control might benefit from simultaneous administration of bezafibrate and a diabetes drug.

**Dyslipidemia market**

**Canada:** The Canadian cholesterol drug market is valued at $1.6 billion while the fibrate sub-market is valued at about $50M. Cholesterol levels are likely to increase with age, with adult men developing heart disease 10 years earlier than adult women on average. Hence, the increased use of cholesterol-lowering drugs among older adults is expected to grow as life expectancy continues to rise. Tribute holds the exclusive license from Actavis (ACT:NYSE) to market Bezalip SR in Canada where according to IMS data it enjoys about 13% share of the fibrate market in that country.

**U.S.:** It is estimated that nearly four million (Ford ES, 2009) people in the U.S. suffer from SHTG. Pharmacological treatment for SHTG (severe hypertriglyceridemia) includes fibrate drugs such as fenofibrate and gemfibrozil and Omega-3 fatty acid (fish oil) products. The combined sale of all of the above fibrate drugs was approximately $3.5 billion in the U.S. in 2013. Research indicates that there is a strong preference for prescribing brand-name over generic fenofibrate products in the United States. Of the cholesterol-lowering drugs, fibrates accounted for 9.4% market share in the U.S. while only 5.3% in Canada as of 2009. Fenofibrates comprised of 75% of the market share of fibrates in the United States (fenofibric acid is not available in Canada).

Tribute has also obtained the exclusive license from Actavis to develop and commercialize Bezalip SR in the U.S. The Investigational New Drug application (IND) submitted to the FDA in the U.S. for the proposed development program for Bezalip® SR tablets was cleared by the regulatory agency in November 2013. The NDA will be the final step required before Tribute can start selling Bezalip SR in the U.S. Tribute expects to exploit the five years of market exclusivity of Bezalip SR in the U.S. that will be available to Tribute upon NDA approval. Tribute has entered into an agreement with JSB-Partners (JSB), a global life sciences advisor with extensive transaction experience and large network of pharmaceutical and biotech contacts, to support Tribute in negotiating contracts related to the co-development and commercialization of Bezalip SR in the U.S. Tribute intends to submit a Special Protocol Assessment (SPA) in the U.S. to establish the safety and efficacy of Bezalip SR.

---

Provided Tribute is able to gain required NDA clearance and significant market share in the U.S., this could be a game-changer for Tribute as the potential market size for Beza lip SR in the U.S. will be much larger than all of the other products in Tribute's portfolio combined.

Abbott Laboratories' (NYSE: ABT) Tricor and Trilipix and are the major players in the fibrate space, and yielded almost $1 billion in U.S. sales in 2011. GlaxoSmithKline's (NYSE: GSK) drug Lovaza, Amarin's Vascepa and AstraZeneca's Epanova, made up of omega-3 fatty acid similar to Beza lip SR, compete for share of this growing dyslipidemia subpopulation. In addition, as Beza lip SR is a sustained release drug that needs to be swallowed whole, patients might prefer this pill (11mm in size) as opposed to the aforementioned drugs that are at least 118% greater in size. However, it remains to be seen if Beza lip SR will be able to gain a significant share of the fibrate market given that it has to compete with a number of established drugs.

**Soriatane**

Soriatane (acitretin) is used for the treatment of severe psoriasis without suppressing the immune system. Soriatane is a registered trademark, Health Canada approved and under license from Actavis Group PTC ehf.

**Pharmacology:** Psoriasis is a skin condition associated with the formation of bubbles or large areas of reddish inflammatory skin and other disorders of keratinization. Soriatane's primary ingredient is acitretin. Acitretin, an organic chemical compound and a synthetic analogue of retinoic acid, is a derivative of vitamin A. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Soriatane®, a prescription medication, works by inhibiting the excessive cell growth, plaque formation and scaling, and keratinization (process by which skin cells become thickened due to the deposition of protein within them), the condition seen in psoriasis (includes erythrodermic and pustular types). Soriatane is involved in the controlled growth and maturation of healthy epidermal cells and affects certain immune reactions in the second dermis. These two mechanisms lead to the formation of the epidermal cells. New epidermal overgrowth can be prevented by the containment of horny scales and existing epidermal overgrowth can be replaced within days. Since it is a very lipophilic (having an affinity for lipids) substance, it penetrates well into tissues.
Psoriasis can be triggered by biological as well as environmental factors. Systemic psoriasis may be treated orally by biologic treatments (ustekinumab (Stelara®), infliximab (Remicade®), etanercept (Enbrel®), alefacept (Amevive®), and adalimumab (Humira®)), cytotoxic agents (Methotrexate®), immunosuppressant’s (cyclosporine), or retinoids. The activity of the immune cells that become overactive in psoriasis is decreased when using biologic treatments. While the biologic agents (TNF-alpha inhibitors) are generally known to be well-tolerated and highly effective, they are significantly more expensive and reimbursement varies widely. Cytotoxic agents work by blocking the function of an enzyme that helps to slow down the rapid overgrowth of skin cells. As the name suggests, immunosuppressant's work by decreasing the activity of the immune system thereby controlling the skin cell overgrowth as seen in psoriasis. Cyclosporine is known to have a rapid onset but is used only as a short-term option. Topical corticosteroids as well as phototherapy offer an alternative treatment option. Acitretin has a slow onset but is known to be most effective as a maintenance therapy, after the disease has been stabilized by other treatment medications.

Psoriasis Market: According to GBI Research, the systemic psoriasis therapeutic market is expected to grow at a CAGR of 11.1% with an increase in disease awareness and diagnosis rates expected to drive the growth in psoriasis treatment. Although generic and non-prescription treatments dominate the market, increase in reimbursement pressures, especially for the biologics, might be the limiting factor in market expansion.

Specialty Care Products
NeoVisc and Uracyst are Tribute’s proprietary products that are developed and manufactured in Canada.

NeoVisc
NeoVisc® is a 1.0% solution of a highly purified, linear high molecular weight sodium hyaluronate which is derived entirely from non-animal sources used to improve joint mobility and reduce joint pain. NeoVisc is available as a single dose (6mL pre-filled syringe) and in a triple dose (2mL pre-filled syringes) format. Tribute is currently the only company in Canada to provide such a product. In addition to Canada, NeoVisc is approved for sales in other international markets, but has not yet been approved in the U.S. Tribute’s most recent approval was in September 2013 from the regulatory office of Hong Kong for the sale of NeoVisc.

Pharmacology: Viscosupplementation is one of the non-pharmacological strategies besides physical therapy and exercise to reduce joint pain and improve joint mobility. Viscosupplementation products may be quite effective when simple pain killers are not. Viscosupplements are administered through an intra-articular injection (injections into the synovial space of the joint, especially the knee). The treatment is localized to the affected area and it helps improve the natural viscosity of the synovial fluid. By increasing lubrication at the joint, joint pain is reduced while joint mobility is improved.

However, it is important to note that the relief period on the single dose may not be as long as the current triple dosed NeoVisc treatment. Visits to the clinic are convenient for the patient as they can make two separate visits for the single dose treatment instead of three consecutive visits for the triple dose treatment annually. Although higher in cost per injection, the single-injection products offer increased convenience for patients in terms of shorter treatment times as well as sufficient dosage for smaller joints. The competitors to the NeoVisc single dose product in Canada include Sanofi’s Synvisc/Synvisc®-One, Pendopharm’s Monovisc® and Bioventus Canada’s Durolane®.

NeoVisc for Osteoarthritis
Patients with osteoarthritis (OA) typically experience pain and loss of mobility due to changes to the internal
environment of the affected joint. An aging population and increase in obesity rates are expected to contribute towards growth in osteoarthritis prevalence. Currently NSAIDs and analgesics are the preferred treatment for OA. Globally, an increase in product awareness among physicians as well as patients opting for specialty medications will likely drive the sales of viscosupplements. Management has estimated that the market for NeoVisc in Canada at roughly $25 million.

**Uracyst**
Uracyst, a sodium chondroitin sulfate solution, is Tribute’s patented technology for the treatment of non-common cystitis and interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Uracyst® is a fluid that is instilled into the bladder. It contains 2% sterile sodium chondroitin sulfate solution and is effective in reducing the symptoms of painful bladder syndrome (PBS/IC).

Tribute outsources the manufacturing of its proprietary products to third party contractors. These facilities are known to be in compliance with Health Canada, and the Canadian Therapeutic Products Directorate (TPD) division medical device guidelines and current Good Manufacturing Practice (cGMP) regulations.

**Pharmacology:**
Bladder surface mucus is composed of glycosaminoglycans (GAGs) and proteoglycans on the outer surface of the transitional cell apical membrane (urothelium that contracts or expands to accommodate the volume of fluid). The glycosaminoglycan layer (GAG) is a mucosal lining of the bladder that acts as a protective barrier against the bladder wall and the urine metabolites. Disruption of this layer is presumed to lead to migration of potassium (and possibly other components of the urine) across the mucosal surface. This results in depolarizing of nerves and muscles and leads to tissue injury and pain. The main symptoms of PBS/IC are painful bladder, increased frequency of urination, and an increased urge to urinate. Since urothelium in IC is dysfunctional and the permeability barrier is lost, restoration and maintenance of the urothelial mucus GAG/proteoglycan layer remains one of the therapeutic measures for PBS/IC. Chondroitin sulfate is believed to be the major proteoglycan responsible for the GAG barrier function, which is lost due to PBS/IC. Uracyst works by replenishing the bladder with a protective coating of chondroitin sulfate, restoring its impermeability.

Interstitial cystitis is managed non-pharmacologically using strategies such as physical therapy, and diet but is treated pharmacologically by restoring the mucus/GAG layer, inhibiting neurological activity, suppression of allergies (anti-histamines), and/or using analgesics (amitriptyline). Drugs for bladder instillation include hyaluronic acid (Cystistat®, Bioniche Life Sciences Inc.), sodium pentosan polysulfate (Elmiron®), Dimethyl sulfoxide (DMSO), Intravesical heparin, Hydrodistension, and sodium chondroitin sulphate solution (Uracyst®). Elmiron is an oral agent used to treat ICs and is known to have a very slow onset. Uracyst provides significant competitive advantages over heparin, pentosan polysulfate, and hyaluronan in simple barrier restoration (curing a dysfunctional urothelium).

(Source: shop.navamedic.com)

**Interstitial Cystitis (Bladder) Market**
The global IC therapeutics market is estimated to grow at a CAGR of 6.3% over the next eight years according to Global Data analysis. As per management’s estimate, the global IC market is valued at $150M. This market is limited in size due to low diagnosis rate, lack of approvals of new products as well as limited availability of existing approved products.
Tribute has global licensing agreements for marketing Uracyst and has long-term patents in the U.S., Canada, Europe and other international territories. The company sells Uracyst in Canada through its own sales force.
Tribute received its second patent in Canada issued July 10, 2012, as Canadian Patent No. 2,515,512 entitled "Cystitis Treatment with High Dose Chondroitin Sulfate". The new patent for Tribute’s proprietary product Uracyst is valid through 2024. The drug is also being sold globally through licensing agreements. Tribute is actively seeking partners and regulatory approvals in Israel, the U.S., China, Japan and South Korea plus other markets globally.

**Collatamp G**
Collatamp G is a fully resorbable, gentamicin-collagen hemostat used both as a surgical implant for hemostasis and for the local delivery of high doses of gentamicin. Collatamp G is made out of collagen, a “natural” substance found in the skin. Collatamp G is a fully resorbable, gentamicin-impregnated collagen "sponge" that can be easily implanted during orthopedic, abdominal, cardiac, plastic or vascular surgery that can reduce the risk of surgical site infections. It provides hemostasis and delivers a high concentration of gentamicin directly to the target tissue. It also provides a localized antibiotic action while maintaining systemic gentamicin levels well below the toxicity threshold.

On June 20, 2012 Tribute acquired the Canadian rights to Collatamp G from Theramed Corporation. Collatamp G is approved in over 50 countries. Collatamp G is a registered trademark and under license from EUSA Pharma (Europe) Limited. The market for such devices is valued at $20M.
FINANCIAL CONDITION

Cash
As of June 30, 2014, the Company had cash and cash equivalents of $2.3M. Cash used in operations for the second quarter of 2014 was approximately $2.3M. The revaluation of the warrant liability related to the private placement in Q1 2013 of about $4.6 million of the Tribute's equity securities resulted in an increase in the warrant expense (non-cash) of $4.6M.

In the general procedure of obtaining licensing and manufacturing agreements and regulatory approvals, Tribute is obligated to pay an up-front licensing fee and additional milestone payments in increments based on aggregate net sales. Management has openly discussed their intentions and ambitions to grow their business through future business development activities such as product acquisitions and licensing. We expect the company will need to raise additional capital as they continue to grow their Canadian business and as they make a push into partnering and selling new products into new but developed markets such as the U.S. This will likely require Tribute to raise additional cash through either debt or equity (or a combination of the two) financing, which they have been successful at doing in the past.

On July 15, 2014, subsequent to Q2 2014, Tribute completed a public offering of common stock of 42,895,00 units issued at a price of $0.70 per unit for gross proceeds of about $30M.

Debt / Liabilities
As of June 30, 2014, Tribute had $12.5M in current liabilities of which $7.7M are warrant liabilities and $7.3M is long-term debt. Tribute entered into a credit agreement with SWK LLC., which provided the company with $8M term loan. The loan matures on August 8, 2018. Interest and principal are paid as a percentage of ongoing revenues. The loan accrues interest at an annual rate of 11.5% plus LIBOR with a minimum interest rate of 13.5%. To the extent that revenues do not cover required interest payments, unpaid interest accrues until paid off in future dates. All unpaid interest principal amounts must be fully paid at maturity of the loan. The loan agreement includes customary events of default such as failure to pay principal and/or interest when due, or failure to comply with covenants. As the company continues to expand, they may secure additional debt financing to maintain operations until they turn cash-flow positive.

VALUATION/RECOMMENDATION

During 2013 Tribute had net sales of $13.4M of which $8.6M was from licensed domestic product sales, $3.4M from other domestic product sales and $1.3M from international product sales. Bezalip SR and Soriatane have been the primary revenue drivers in Tribute’s portfolio of licensed domestic products contributing more than 65% of total sales. Our model assumes that these two products continue to drive the bulk of revenue in Canada and (perhaps conservatively) estimate sales for these two drugs doubling by 2016. By the end of 2013, CAMBIA had gained more than 1% market share in Canada. We see CAMBIA sales pick up traction. This can be attributed to management's strategy to launch widely among general practitioners (GPs), immense support from the key opinion Leaders (KOLs) as well as reimbursements obtained from private healthcare facilities. Although CAMBIA cannot compete with generics on volume, we expect CAMBIA can capture approximately 5% market share by 2016 as the drug benefits from its market exclusivity and leverages advantages over other migraine medications. Other domestic product and international sales are primarily driven by Uracyst, NeoVisc and Collatamp G. Uracyst and NeoVisc, with combined international sales of $1.2M as of December 31 2013, have provided the bulk of the revenues. While the sales pattern is unpredictable due to changes in the global economy, variations in regulatory approvals, and disease diagnosis, management believes that their international business is picking up which will help in their proprietary product sales overseas as they expand their business into new territories. We expect a modest growth rate for Uracyst and NeoVisc and model revenue from these two products to reach $2 million by 2017. We do not currently model revenues for Bezalip SR in the U.S. as regulatory approval has yet to be attained.
For the year 2013 cost of goods sold (COGS) was about 65% of revenue for Bezalip and Soriatane and 30% for CAMBIA. COGS are inherently higher for in-licensed products as they include sales and distribution fees, tiered milestone payments and royalties. Sales and distribution fees for Bezalip SR and Soriatane are payable as a percentage of net sales up to a baseline revenue. Additionally, there are incremental fees for sales above this baseline amount. As a result, total COGS for Bezalip and Soriatane will be lower as sales increases (i.e. - gross margins will expand). We model COGS at 61% of net sales for Bezalip SR and Soriatane in 2014 with a gradual reduction as revenues increase over time.

Selling, general and administrative (SG&A) expenses was roughly 73% of net sales in 2013. Management attributed this to the initial launch of their pipeline product, CAMBIA, including costs related to development of physician samples, training materials and slide kits for KOLs. Since most of the costs associated with the promotion of CAMBIA have already been invested, we do not anticipate incremental operating expenses related to sales and marketing of the product. As such, we expect SG&A as a percentage of total net revenue to reduce over the next 5 years assuming no additional products are added to their portfolio.

The pharmaceutical industry is a regional market served by very few specialty pharmaceutical companies, such as Tribute. Management believes that Tribute has a competitive advantage within its chosen therapeutic areas over other Canadian companies or multi-national subsidiaries seeking to license or acquire products in Canada. Tribute has been strategic in acquiring licensed products that have high revenue potential in diverse markets. When paired with their operational efficiencies, we expect them to achieve positive cash flow in near term. Tribute is gaining traction as the company has adopted the route to rapidly and effectively target smaller market niches that have a need for specific drugs. Tribute also holds defendable patents for certain of its products. As Tribute continues to develop new partnerships and further expand its business in the U.S. and Canada, there is a possibility of seeing new pharmaceutical products being added to their portfolio. Tribute has seen consistent growth in domestic sales from its proprietary as well as in-licensed products. CAMBIA, Bezalip SR and Soriatane are expected to provide the bulk of revenue and drive earnings in the future. A portion of the finance from the gross proceeds is expected to be used for expanding business, in acquisition and licensing opportunities in Canada. Management has several opportunities under evaluation and is looking into expanding its portfolio with complementing products or products used by a large set of population. Although such a step can have a significant bearing on debt pay off we feel that Tribute may become profitable over time.

Valuation:
TBUFF currently trades at $0.56/share, well below our calculated and targeted fair value. We utilized a risk-adjusted Net Present Value (NPV) analysis to determine our price target objective. Using a Discounted Cash Flow (DCF) analysis, we derive the total equity value of approximately $63 million, assuming 63.6 million fully-diluted shares outstanding and roughly $12.00 million in cash by end of 2016. Tribute’s exclusive license to market Bezalip SR in the U.S. is dependent on the NDA approval as a final step. We will incorporate the contribution from sales of Bezalip SR in the U.S. as we near the completion of the FDA approval process as well as the contribution from sales of Bilastine in Canada as we near the completion of the Health Canada approval process.

We have made minor modifications to our financial model to reflect the recent earnings. We maintain our Outperform rating for TBUFF with a price target of $1.00/share.
RISKS

Patent cliff: As branded drugs near patent expiration, the loss of drug exclusivity could significantly reduce Tribute's revenue growth going forward. As such branded drugs compete against generic alternatives that are cheaper.

Customer Concentration: More than 50% of Tribute’s entire product sales are from three wholesale customers. The loss of any one of the customers due to economic downturns, changing market scenarios, or for any other reason could reduce order volumes resulting in decreased revenues.

Regulatory Approvals: Tribute is involved in the acquisition of pharmaceutical products that have yet to be approved by regulatory agencies in the respective territories they are marketed in. This is an extensive process that tends to be time-intensive in nature. The evolving regulatory compliance issues of local government agencies may cause further delays or non-approvals that could negatively impact Tribute's business.

Reimbursement: The increase in use of premium-priced drugs (complexity of manufacturing, special storage and handling, patient-specific dosing, and mode of administration) has changed the reimbursement landscape considerably. Despite the global economic recovery, cost pressures can result in lower levels of reimbursement that might constrain the sales of specialty pharmaceutical products such as those offered by Tribute.

Generic Equivalents: Although the specialty-care drugs are difficult to replicate after patent expiration, they are quite often challenged by the generics industry. Generic companies are well-positioned to be the alternative healthcare solution, providing low-cost, reasonably high-quality drugs that could reduce Tribute’s market share.
## PROJECTED FINANCIAL STATEMENT

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>$13,440.4</td>
<td>$3,493.6</td>
<td>$4,041.3</td>
<td>$4,075.0</td>
<td>$4,467.1</td>
<td>$16,037.2</td>
<td>$21,482.2</td>
<td>$26,762.2</td>
<td>$32,060.3</td>
<td>$37,378.1</td>
</tr>
<tr>
<td><strong>Cost of Goods Sold</strong></td>
<td>$7,386.2</td>
<td>$1,758.9</td>
<td>$1,987.5</td>
<td>$2,056.5</td>
<td>$7,737.4</td>
<td>$9,408.7</td>
<td>$11,468.7</td>
<td>$13,758.1</td>
<td>$16,053.4</td>
<td></td>
</tr>
<tr>
<td><strong>Write down of inventories</strong></td>
<td>$56.9</td>
<td>$0.0</td>
<td>$13.4</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td></td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td>$5,997.3</td>
<td>$1,734.7</td>
<td>$2,040.4</td>
<td>$2,140.5</td>
<td>$2,410.6</td>
<td>$8,299.8</td>
<td>$12,073.6</td>
<td>$15,293.5</td>
<td>$18,302.2</td>
<td>$21,324.7</td>
</tr>
<tr>
<td><strong>SG&amp;A</strong></td>
<td>$9,830.1</td>
<td>$3,222.7</td>
<td>$2,409.7</td>
<td>$2,241.25</td>
<td>$2,367.6</td>
<td>$10,241.2</td>
<td>$13,319.0</td>
<td>$13,916.4</td>
<td>$14,427.1</td>
<td>$14,951.2</td>
</tr>
<tr>
<td><strong>D&amp;A</strong></td>
<td>$1,245.8</td>
<td>$290.35</td>
<td>$296.57</td>
<td>$244.50</td>
<td>$245.69</td>
<td>$1,088.51</td>
<td>$1,331.90</td>
<td>$1,391.64</td>
<td>$1,442.71</td>
<td>$1,495.12</td>
</tr>
<tr>
<td><strong>Operating Income</strong></td>
<td>($5,078.7)</td>
<td>($1,778.3)</td>
<td>($665.8)</td>
<td>($345.3)</td>
<td>($202.6)</td>
<td>($3,029.9)</td>
<td>($2,577.3)</td>
<td>($14.4)</td>
<td>$2,432.4</td>
<td>$4,878.3</td>
</tr>
<tr>
<td><strong>Net Interest Expense</strong></td>
<td>$523</td>
<td>$267</td>
<td>$298.01</td>
<td>$298.01</td>
<td>$298.01</td>
<td>$1,069.00</td>
<td>$1,069.00</td>
<td>$1,069.00</td>
<td>$1,069.00</td>
<td>$1,069.00</td>
</tr>
<tr>
<td><strong>Accretion Expense</strong></td>
<td>$104</td>
<td>$31</td>
<td>$34.41</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td><strong>Loss on Disposal of equipment/asset</strong></td>
<td>$399</td>
<td>$1,212</td>
<td>$3,402.78</td>
<td>$262.04</td>
<td>$107.93</td>
<td>$5,049.53</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td><strong>Operating Margin</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7.6%</td>
<td>21.1%</td>
<td>11.9%</td>
<td>10.4%</td>
<td></td>
</tr>
<tr>
<td><strong>Change in Derivative/Warrant Valu</strong></td>
<td>$379</td>
<td>$1,113</td>
<td>$1,402.78</td>
<td>$262.04</td>
<td>$107.93</td>
<td>$5,049.53</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td><strong>Net Income</strong></td>
<td>($6,887.2)</td>
<td>($3,288.2)</td>
<td>($4,401.0)</td>
<td>($905.3)</td>
<td>($673.6)</td>
<td>($9,148.4)</td>
<td>($3,646.3)</td>
<td>($1,083.4)</td>
<td>$1,363.4</td>
<td>$3,809.3</td>
</tr>
<tr>
<td><strong>Taxes (benefit)</strong></td>
<td>$314.9</td>
<td>$0.0</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td><strong>Tax Rate</strong></td>
<td>35.0%</td>
<td>35.0%</td>
<td>15.0%</td>
<td>15.0%</td>
<td>15.0%</td>
<td>15.0%</td>
<td>15.0%</td>
<td>15.0%</td>
<td>15.0%</td>
<td>15.0%</td>
</tr>
<tr>
<td><strong>Net Margin</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-17.0%</td>
<td>-4.4%</td>
<td>-2.7%</td>
<td>-3.9%</td>
<td>-3.9%</td>
</tr>
<tr>
<td><strong>EPS</strong></td>
<td>($0.13)</td>
<td>($0.06)</td>
<td>($0.09)</td>
<td>($0.02)</td>
<td>($0.01)</td>
<td>($0.17)</td>
<td>($0.06)</td>
<td>($0.02)</td>
<td>$0.02</td>
<td>$0.05</td>
</tr>
<tr>
<td><strong>Diluted Shares O/S</strong></td>
<td>49,169</td>
<td>51,420</td>
<td>51,581</td>
<td>52,775</td>
<td>55,000</td>
<td>52,771</td>
<td>60,204</td>
<td>62,978</td>
<td>64,793</td>
<td>71,684</td>
</tr>
</tbody>
</table>
MANAGEMENT TEAM

Rob Harris
President and CEO
Rob Harris has 35 years of pharmaceutical industry experience in both Canada and the United States in sales, marketing, business development and general management. Prior to co-founding Tribute Pharmaceuticals, Rob was the President & CEO of Legacy Pharmaceuticals Inc. Rob also has previous experience at Biovail Corporation where as VP of Business Development he was involved, led and successfully concluded numerous business development transactions, including the licensing of new chemical entities, the acquisition of mature products, the completion of co-promotion deals, distribution agreements, product development and reformulation transactions. Rob joined Biovail in 1997 as the GM of Biovail Pharmaceuticals Canada at a time when the company experienced rapid growth in the Canadian division. Before Biovail, Rob worked in various senior commercial management positions during his twenty-year tenure at Wyeth (Ayerst) and has been involved in numerous product launches during his career.

Scott Langille
Chief Financial Officer
Scott Langille has over 25 years of experience in the pharmaceutical industry in both Canada and the United States. Prior to Tribute Pharmaceuticals, Scott was Chief Financial Officer of Virexx Medical Corp, a biotechnology company located in Alberta listed on the American Stock Exchange and the Toronto Stock Exchange. Scott was responsible for strategic direction, business development initiatives, investor relations, corporate financing activities, and financial operations. Past financial experience includes Director, Corporate Finance at Biovail Corporation, Director of Finance at Biovail Pharmaceuticals Canada, Biovail's sales and marketing division in Canada as well as Vice President at Biovail Pharmaceuticals Inc., Biovail's sales and marketing division in the United States. Other prior management positions include Director Finance at AltImed Pharmaceuticals Company and Controller at Zimmer Canada. Scott has a professional accounting designation and an MBA from the University of Toronto.

Dr. Bernard Chiasson
Chief Scientific Officer
Dr. Bernard Chiasson, Ph.D. has nearly two decades of experience in working with the pharmaceutical and biotechnology industry. He has held positions of increasing responsibility in R and D including drug discovery, medical affairs, business development and licensing, regulatory affairs and executive management. Bernie has successfully patented technologies in the area of neuroscience and has worked on several small molecules, biologics and biotechnology products at all stages of development including the final registration phase with Health Canada and the US FDA. He is a trained Neuroscientist and Pharmacologist. He has created development and commercialization strategies as well as franchise management approaches for various categories including Hematology, Oncology, Inflammation and Nephrology. He has obtained his industry training with Novartis, Draxis, Bayer, Amgen and OptumInsight. Most recently, Bernie was VP of US Strategic Regulatory Affairs and Global Medical Services at OptumInsight where he was responsible for a team of scientists and physicians supporting client drug development, safety and regulatory strategies and operations. Bernie received his University training at Dalhousie University and the University of Toronto.

Janice Clarke
V.P. Finance & Administration
Janice Clarke has over twenty years of office administration and financial management experience with proven abilities to implement and manage various financial systems and office procedures. Janice joined Stellar Pharmaceuticals Inc. in August 2000 and currently manages its administrative and financial processes.

Ann Hartshorn
V.P. Marketing
Ann has over 25 years of experience in the pharmaceutical industry with progressive positions spanning sales and marketing, new product launches, and life cycle management throughout various therapeutic areas with family practice and specialized medicine. Prior to joining Tribute Pharmaceuticals, Ann was a principal of a pharmaceutical consulting firm that assisted numerous international pharmaceutical companies in their life cycle management activities, including Astra Zeneca, Servier Pharma, and Pfizer. Prior to her consulting activities, Ann was Director, Hospital and Specialty Business Unit for Crystaal Corporation in which capacity she successfully launched several products in Canada. While at Crystaal, Ann also served as Director of Marketing and Director of New Product
Planning. Ann also has previous marketing experience with Wyeth and AstraZeneca. Born and educated in England, Ann graduated from the University of Reading and the Royal Berkshire Hospital as a State Registered Nurse and Midwife. After immigrating to Canada, she worked in the ICU, CCU and NICU at Ottawa Civic and Ottawa General Hospitals.

Murray Roach  
**VP Sales**
Mr. Roach has 20 years of pharmaceutical sales and marketing experience in Canada, including Vice President, Sales and Marketing for Taro Pharmaceuticals in Canada. In this capacity Mr. Roach gained an extensive experience in the dermatology market nationally in all aspects of the business. Prior to Taro Pharmaceuticals, Mr. Roach spent 15 years at Wyeth Canada in several senior sales and marketing positions including Director of Sales, Pharmaceuticals, Director of Sales, Biopharmaceuticals and Product Manager for Effexor® (venlafaxine). Mr. Roach enjoyed many years of success at Wyeth Canada and won numerous sales and marketing awards during his career with Wyeth. He began his career with Wyeth as a sales representative in Saskatchewan and is a graduate of the University of Saskatchewan, College of Education.

David Butts  
**B.SC., V.P. International Business**
David Butts V.P., International Business is a senior executive with over 25 years in the life sciences industry with progressive sales, marketing and clinical experience. He has a proven track record and success in the area of new business development and product licensing. A graduate from Carleton University, Ottawa, Mr. Butts has a good knowledge of the clinical development process and experience in many key pharmaceutical segments; urology, orthopedics, respiratory, allergy and cardiology.

Paul MacPherson  
**V.P. Manufacturing & Operations**
Paul joined Tribute in May 2007, with 15 years of experience in process engineering and production within the pharmaceutical and biotech fields. He holds Bachelor’s and Master’s Degrees in Chemical Engineering from McMaster University.

Darrin Statchuk  
**Director of Quality & Regulatory Affairs**
Darrin Statchuk, Director of Quality and Regulatory Affairs, joined the company in 2004. Mr. Statchuk has over 15 years of experience in the manufacturing sector specializing in Quality Management and Regulatory aspects for both large and small international companies. Darrin graduated from the University of Western Ontario, where he earned his Bachelor of Science in Chemistry.

Luigi Berardelli  
**Director Specialty Products**
Luigi Berardelli, Director of Sales and Marketing for Tribute’s Specialty Care Group has over 20 years of experience in the pharmaceutical market in Canada. Past experience includes Business Unit Director for Synvisc/Surgical Devices at Genzyme (now Sanofi), Director of Sales at Biovail's Canadian operations and Director of Sales at Rhone Poulenc Canada.

Jesse Ledger  
**Director of Business Development**
Jesse Ledger, Director of Business Development has over 10 years of industry experience. Previous experience includes Director of Business Development for Sterimax Inc., where he was responsible for numerous licensing transactions and Manager of Business Development at Methapharm Inc. Jesse has an honours BBA from Trent University in Peterborough, Ontario.
DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Anita Dushyanth, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

POLICY DISCLOSURES

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1085 companies whose securities it covers, including securities covered by Zacks SCR:

- Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.
- Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.
- Sell/Underperform: The analyst expects that the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 16.5%, Hold/Neutral- 75.4%, Sell/Underperform – 7.0%. Data is as of midnight on the business day immediately prior to this publication.